NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
school
University Rankings
subject
University Subject Rankings
insights
Subject Rankings
place
Country Rankings
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Seyda Gunduz
Memorial Healthcare Group - / Türkiye
Others
AD Scientific Index ID: 4969559
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Seyda Gunduz's MOST POPULAR ARTICLES
1-)
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial T Powles, T Csőszi, M Özgüroğlu, N Matsubara, L Géczi, SYS Cheng, ... The Lancet Oncology 22 (7), 931-945, 2021 1772021
2-)
Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study M Gunaldi, S Goksu, D Erdem, S Gunduz, Y Okuturlar, E Tiken, ... International journal of clinical and experimental medicine 8 (4), 5937, 2015 742015
3-)
LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361 A Alva, T Csőszi, M Ozguroglu, N Matsubara, L Geczi, SYS Cheng, ... Annals of Oncology 31, S1155, 2020 732020
4-)
Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancerS Gunduz, H Mutlu, D Tural, Ö Yıldız, M Uysal, HS Coskun, H BozcukAsia‐Pacific Journal of Clinical Oncology 11 (4), 288-292, 2015762015
5-)
Prognostic significance of p53 in gastric cancer: a meta-analysisM Yildirim, V Kaya, O Demirpence, S Gunduz, H BozcukAsian Pacific Journal of Cancer Prevention 16 (1), 327-332, 2015592015
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept